Data will be provided on a rolling basis, as the companies receive the latest numbers
Pfizer and BioNTech have started a biologics license application (BLA) with FDA for approval of their two-dose mRNA vaccine to prevent Covid-19 in people 16 years of age and older. The companies will be providing the necessary figures to support the BLA on a rolling basis over the coming weeks, with a request for priority review. Once the BLA is complete and formally accepted for review by FDA, the agency can set the Prescription Drug User Fee Act (PDUFA) goal date for a decision.
Currently, the vaccine is available in the US under emergency use authorization (EUA), having been the first Covid vaccine to receive that designation in America, followed by Moderna (also two jabs) and Johnson & Johnson (one shot), respectively. Since then, Pfizer-BioNTech have delivered more than 170 million doses of the vaccine across the country.
Pfizer and BioNTech began the BLA by submitting the nonclinical and clinical data needed to support licensure of the Covid-19 vaccine for use in individuals 16 years of age and older. This includes the most recent analyses from the Phase III clinical trial, where the vaccine’s efficacy and favorable safety profile were observed up to six months after the second dose.
Pfizer and BioNTech have also submitted an application to expand the current EUA for their vaccine to include adolescents 12 to 15 years of age. The companies plan to submit a supplemental BLA to support licensure of the vaccine in this age group once the mandatory data on six months after receiving the second vaccine dose are available.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.